Measles elimination status

## 2015 endemic

2016 endemic

Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

National plan of action


Source: Measles and rubella elimination Annual Status Update report, 2016
ND= Data not available
Measles and rubella immunization schedule, 2016

|  | Vaccine | Schedule | Year of introduction |  |
| :---: | :---: | :---: | :---: | :---: |
| MCV1 | MMR | 1 year | MCV2 | 1971 |
| MCV2 | MMR | 6 years | RCV | 1976 |
| Measles vaccination in school |  |  |  | Yes |

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance MMR = measles-mumps-rubella-containing vaccine; MCV1 = first dose measles-containing vacccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Definition used for an outbreak


Source: Measles and rubella elimination Annual Status Update report, 2016

Rubella elimination status

## 2015 endemic <br> 2016 endemic

Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

Demographic information, 2016

| Total population | 3802134 |
| :---: | :---: |
| < 1 year old | 33358 |
| < 5 years old | 166083 |

Source: World Population Prospects: The 2015 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2007-2016


Source:Disease incidence and immunization coverage, WHO, Data and Statistics,
Immunization Monitoring and Surveilance
MCV1 = first dose of measles-containing vaccine
MCV2= second dose of measles-containing vaccine

Confirmed measles cases by month of onset, 2012-2016


Source: CISID2 2016

Measles cases by first subnational level, 2016


Source: Measles and rubella elimination Annual Status Update report, 2016

Measles genotypes by first subnational level, 2016


Source: MeaNS 2016
(Note: no subnational genotype information available)

Note: The dots in the maps are placed randomly within the administrative regions
Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Measles cases by age group and vaccination status, 2016


Source: Measles and rubella elimination Annual Status Update report, 2016 (No age group and vaccination status data submitted)

Sources of infection, 2016

|  | Measles | Rubella |
| :---: | :---: | :---: |
| Imported | 0 | 0 |
| Import-related | 0 | 0 |
| Unknown/ Not <br> reported | 5 | 0 |
| Endemic | 132 | 16 |

[^0]Information on CRS, 2016

## No cases reported



[^1]CRS = congenital rubella syndrome

Measles incidence, epidemiologic and virologic characteristics, 2012-2016

|  | Suspected measles cases | Confirmed measles cases |  |  |  | Discarded <br> as <br> non- <br> measles | Measles incidence | Genotypes detected |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Laboratory | Epilinked | Clincally | Total |  |  |  |
| 2012 | ND | 0 | 0 | 25 | 25 | ND | 5.9 | NA |
| 2013 | 10 | 0 | 0 | 17 | 17 | 1 | 2.6 | ND |
| 2014 | 5048 | 140 | ND | 4880 | 5048 | 99 | 1281.3 | ND |
| 2015 | 4105 | 351 | 231 | 4084 | 4666 | 126 | 531.3 | D8 |
| 2016 | 162 | 119 | 0 | 43 | 162 | 36 | 42.6 | ND |

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
ND = Data not available; $\mathrm{NA}=$ = N t applicable

Rubella incidence, epidemiologic and virologic characteristics, 2012-2016

|  | Suspected rubella cases | Confirmed measles cases |  |  |  | $\begin{gathered} \text { Discarded } \\ \text { as } \\ \text { non- } \\ \text { rubella } \end{gathered}$ | Rubella incidence | Genotypes detected |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Laboratory | Epi- linked | Clincally | Total |  |  |  |
| 2012 | ND | 0 | 0 | 17 | 17 | ND | 9.3 | ND |
| 2013 | 7 | 0 | 0 | 7 | 7 | 0 | 1.9 | ND |
| 2014 | 8 | 5 | 0 | 3 | 8 | 0 | 2.1 | ND |
| 2015 | 12 | 9 | ND | 3 | 12 | 3 | 1.9 | ND |
| 2016 | 22 | 15 | 0 | 7 | 22 | 7 | 5.8 | ND |

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2012-2016

|  | Discarded <br> non- <br> measles <br> rate | \% 1st sub- <br> national <br> unit with <br> $\geqslant 2$ <br> discarded <br> cases | \% cases <br> with <br> adequate <br> laboratory <br> investiga- <br> tion | \% origin of <br> infection <br> known | $\#$ <br> specimen <br> tested for <br> measles | \% positive <br> for <br> measles | Rate of <br> viral <br> detection | \% WHO <br> and <br> proficient <br> labs |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2012 | ND | ND | NA | ND | ND | ND | ND | ND |
| 2013 | $20 \%$ | NA | $20 \%$ | $0 \%$ | ND | ND | 0 | ND |
| 2014 | 0.4 | ND | 0.1 | $0 \%$ | 254 | 0.7 | 0 | ND |
| 2015 | 0.0 | ND | 0.1 | $0 \%$ | 640 | 0.7 | 0 | $100 \%$ |
| 2016 | 1.0 | ND | 0.1 | $100 \%$ | 36 | 0.4 | 0 | $47 \%$ |

Source: MR LDMS 2012-2016, CISID2 2012-2016, ASU 2016 and laboratory accreditation results 2012-2016
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

## Rubella surveillance and laboratory performance indicators,

 2012-2016|  | Discarded <br> non- <br> rubella <br> rate | \% 1st sub- <br> national <br> unit with <br> $\geq 2$ <br> discarded <br> cases | \% cases <br> with <br> daequate <br> laboratory <br> investiga- <br> tion | \% origin of <br> infection <br> known | $\#$ <br> specimen <br> tested for <br> rubella | \% positive <br> for rubella | Rate of <br> viral <br> detection | \% WHO <br> and <br> porficient <br> labs |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2012 | ND | ND | ND | ND | ND | ND | ND | ND |
| 2013 | NA | NA | $0 \%$ | $0 \%$ | ND | ND | 0 | ND |
| 2014 | NA | NA | ND | $0 \%$ | 3451 | 0.0 | 0 | ND |
| 2015 | 0 | ND | $0 \%$ | $0 \%$ | 302 | 0.1 | 0 | $100 \%$ |
| 2016 | 0.2 | ND | $68 \%$ | $0 \%$ | 30 | $100 \%$ | 0 | ND |

Source: MR LDMS 2012-2016, CISID2 2012-2016, ASU 2016 and laboratory accreditation results 2012-2016
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

## RVC comments, based on 2016 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) recognizes the complex circumstances and commends the country for continued efforts to put in place strategies to improve coverage and surveillance. The RVC appreciates the National Verification Committee's (NVC) efforts to provide a complete and comprehensive ASU, and encourages the NVC to continue cooperating with the RVC Secretariat in preparation of the next ASU.
The RVC is concerned about the size of the susceptible population in the country and urges action to increase measles and rubella immunity in all population groups throughout the country. If SIAs are considered, they should be thoroughly planned, synchronized in both entities and district, and urgently performed. Surveillance needs to be strengthened, including increasing the rates of laboratory investigation and viral detection of measles and rubella through the submission of specimens to a WHO-accredited laboratory for $\lg \mathrm{M}$ testing and for genotyping. Further activities should be considered as a matter of urgency.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

## Surveillance performance indicators and targets

a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100000 population
b. $\%$ cases with adequate laboratory investigation: $\geqslant 80 \%$
c. \% origin of infection known: $\geqslant 80 \%$
d. Rate of viral detection: $\geqslant 80 \%$


[^0]:    Source: Measles and rubella elimination Annual Status Update report, 2016

[^1]:    Source: Measles and rubella elimination Annual Status Update report, 2016

